Arca
Skip to content
Tools
Tools

Glutamate receptor ionotropic AMPA

Complex group in Homo sapiens that 14 drugs act on.

  • Drugs that act on it: 14
  • Approved: 2
  • In phases 1 to 3: 12
  • Sponsors: 9
  • Genes: 4

Who is on it, and how far along

Every drug ChEMBL records acting on GRIA1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 12
  • Other 2

Approved2

  • Topiramate
  • Perampanel

Phase 30

    Phase 212

    • Osavampator
    • Becampanel
    • CX1739
    • Dasolampanel
    • Farampator
    • Irampanel
    • Mibampator
    • MK-8777
    • Pesampator
    • Selurampanel
    • Tezampanel anhydrous
    • Zonampanel

    Phase 10

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 8 of 14 act as: Glutamate receptor ionotropic AMPA antagonist; the rest name their own mechanism.
      TopiramateApprovedJohnson & JohnsonSmall moleculeAntagonist31
      PerampanelApprovedCatalyst PharmaceuticalsSmall moleculeAntagonist9
      OsavampatorPhase 2Neurocrine BiosciencesSmall moleculePositive allosteric modulatorGlutamate receptor ionotropic AMPA positive allosteric modulator4
      BecampanelPhase 2—Small moleculeAntagonist0
      CX1739Phase 2—OtherPositive allosteric modulatorGlutamate receptor ionotropic AMPA positive allosteric modulator0
      DasolampanelPhase 2—Small moleculeAntagonist0
      FarampatorPhase 2—Small moleculePositive allosteric modulatorGlutamate receptor ionotropic AMPA positive allosteric modulator0
      IrampanelPhase 2—Small moleculeAntagonist0
      MibampatorPhase 2Eli LillySmall moleculePositive allosteric modulatorGlutamate receptor ionotropic AMPA positive allosteric modulator0
      MK-8777Phase 2Merck & Co. (MSD)OtherPositive allosteric modulatorGlutamate receptor ionotropic AMPA positive allosteric modulator0
      PesampatorPhase 2BiogenSmall moleculePositive allosteric modulatorGlutamate receptor ionotropic AMPA positive allosteric modulator0
      SelurampanelPhase 2Novartis PharmaceuticalsSmall moleculeAntagonist0
      Tezampanel anhydrousPhase 2TorreyPines TherapeuticsSmall moleculeAntagonist0
      ZonampanelPhase 2Astellas PharmaSmall moleculeAntagonist0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 20 in all, from ClinicalTrials.gov.
      Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1sTopiramatePhase 4Not yet recruitingJing LuoSep 21, 2026
      Discontinuing Psychotropic Medication Before Psychotherapy for PTSDTopiramate—Not yet recruitingAcademic Centre for Dentistry in AmsterdamSep 3, 2026
      Obesity Treatment With Phentermine-Topiramate ER in AYA Surviving Leukemia and LymphomaTopiramatePhase 2Not yet recruitingSt. Jude Children's Research HospitalAug 27, 2026
      Pragmatic Trial to Study the Cost-Effectiveness of MyPhenome-RX Test to Guide Anti-Obesity PharmacotherapyTopiramateNot applicableNot yet recruitingPhenomix SciencesJul 27, 2026
      Idiopathic Intracranial Hypertension: Prognostic Factors and Multidisciplinary ManagementTopiramateNot applicableActive, not recruitingSohag UniversityJul 16, 2026
      Comparing Migraine Preventive Therapies vs. Anti-CGRP Therapies for Tinnitus in Patients With Migraine (COMPACT-PM)TopiramatePhase 4Not yet recruitingStanford UniversityJun 17, 2026
      Neurophysiological Effects of Medication Tapering During Treatment With Spinal Cord StimulationTopiramate—RecruitingBrai²nFeb 17, 2026
      Combining Latency Reversing Agents to Address the HIV ReservoirTopiramatePhase 1 / Phase 2Not yet recruitingErasmus Medical CenterFeb 3, 2026
      Senicapoc and Perampanel for Newly Diagnosed GlioblastomaPerampanelEarly phase 1RecruitingAarhus University HospitalDec 16, 2025
      A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)OsavampatorPhase 3RecruitingNeurocrine BiosciencesSep 29, 2025
      NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)OsavampatorPhase 3RecruitingNeurocrine BiosciencesMay 8, 2025
      NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)OsavampatorPhase 3RecruitingNeurocrine BiosciencesApr 4, 2025
      Study to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)OsavampatorPhase 3RecruitingNeurocrine BiosciencesJan 22, 2025
      A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized Tonic- Clonic SeizuresPerampanel—RecruitingEisai Co., Ltd.Oct 24, 2024
      PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac ArrestPerampanelPhase 2RecruitingUniversity of California, San FranciscoMay 7, 2024
      Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine ResponsePerampanelPhase 1RecruitingYale UniversityJun 22, 2023
      The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal EffectsPerampanelPhase 2RecruitingYale UniversityMar 27, 2023
      Antiepileptic Drugs in Elderly PatientsPerampanel—RecruitingWei ZhaoJul 15, 2022
      Implantable Microdevice In Primary Brain TumorsPerampanelEarly phase 1RecruitingOliver JonasOct 23, 2019
      A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood EpilepsyPerampanelPhase 2Active, not recruitingEisai Inc.Jul 10, 2019

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2096670, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.